Related Experiment Video
Updated: Jul 15, 2026

Intravital Microscopy and Thrombus Induction in the Earlobe of a Hairless Mouse
Published on: April 2, 2017
[Skin and mucosal ulcerations in heparin-induced thrombocytopenia (HIT) II]
1Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstrasse 55, 45122 Essen.
Abstract:
About 0.1-2% of patients receiving heparin develop heparin-induced thrombocytopenia type II (HIT II) which is caused by antibodies directed against heparin-platelet factor 4 (PF4) complexes. Activation of thrombocytes and endothelial cells can lead to thrombocytopenia, venous and arterial thrombosis or thromboembolic events 10-14 days after the first dose. HIT II has a high mortality rate because of pulmonary emboli, cerebrovascular accidents, myocardial and limb infarctions. A 55-year-old patient with HIT II presented with arterial and venous thromboses and a silent myocardial infarction. In addition, he showed extensive skin and mucosal necrosis, an uncommon complication. Rheologic therapy with danaparoid Natrium, alprostadil alfadex and acetylsalicylic acid in combination with percutaneous transluminal angioplasties as well as local and systemic antiinflammatory therapy prevented further progression of the disease.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Endocarditis II: Clinical Features of Infective Endocarditis
Inflammatory Bowel Disease II: Ulcerative Colitis
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology
Healing II: Complications